<DOC>
	<DOCNO>NCT00003425</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Chemoprotective drug amifostine may protect normal cell side effect chemotherapy . PURPOSE : Phase I/II trial study effectiveness high-dose melphalan plus peripheral stem cell transplantation amifostine treat patient cancer .</brief_summary>
	<brief_title>Phase I/II Study Escalating-Dose Melphalan w/Autologous SCS &amp; Amifostine Cytoprotect</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose high dose melphalan autologous peripheral blood stem cell support amifostine cytoprotection patient cancer . II . Determine complete response rate , event free survival , overall survival , nonrelapse mortality patient population . OUTLINE : This dose escalation study melphalan . Prior high dose melphalan amifostine cytoprotection , patient may receive cyclophosphamide IV . Filgrastim ( G-CSF ) give cytapheresis complete . Patients receive high dose melphalan accord escalate dose schedule . High dose melphalan administer IV day -1 . Amifostine also administer day -2 -1 . Peripheral blood stem cell transplantation perform day 0 . Dose escalation high dose melphalan continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 8 patient experience dose limit toxicity . After MTD high dose melphalan determine , additional patient treat dose level . Patients follow day 30 , 100 , 365 , yearly thereafter . PROJECTED ACCRUAL : After determination MTD , total 14-25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis primary tumor and/or recurrence low curative potential use therapy , include limited : Acute leukemia Myeloma Breast cancer Ovarian cancer Hodgkin 's disease NonHodgkin 's lymphoma Neuroblastoma Ewing 's sarcoma In absence recurrence , malignancy autotransplant regimen consider reasonable therapeutic alternative also consider Greater 25 % bone marrow normal cellularity le 10 % volume compose tumor cell No active brain metastasis carcinomatous meningitis ( control CNS metastasis eligible ) PATIENT CHARACTERISTICS : Age : 14 70 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3000/mm3 Absolute neutrophil count great 1500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin , SGOT , SGPT le 2 time normal Renal : Creatinine clearance great 60 mL/min Cardiovascular : LVEF least 45 % Pulmonary : DLCO least 50 % FEV1 least 60 % Other : Not pregnant nursing Fertile patient must use effective contraception HIV , HTLV1 , HTLV2 negative Hepatitis B C negative PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior autologous peripheral blood stem cell transplant Chemotherapy : Cumulative anthracycline equivalent dose great 450 mg/m2 Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Recovered prior therapy No antihypertensives 24 hour prior amifostine administration</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>